Clinical Scorecard: FDA Expands Marstacimab Indication in Hemophilia A and B
At a Glance
Category
Detail
Condition
Hemophilia A and B
Key Mechanisms
Targets the Kunitz 2 domain of tissue factor pathway inhibitor (TFPI) to restore balance between bleeding and coagulation.
Target Population
Patients aged 12 years and older with hemophilia A or B with inhibitors and pediatric patients aged 6 to 11 years with or without inhibitors.
Care Setting
Outpatient setting for routine prophylaxis.
Key Highlights
Marstacimab is the first subcutaneous non-factor therapy for pediatric patients with hemophilia B aged 6 to 11 years.
Mean treated annualized bleeding rate (ABR) reduced by 93% compared to on-demand intravenous treatment.
No routine treatment-related laboratory monitoring required.
Dosing varies by age group: 150 mg loading dose for ages 6-11, 300 mg for ages 12-17.
Common adverse reactions include injection-site reactions, headache, and pyrexia.
Guideline-Based Recommendations
Diagnosis
Diagnosis of hemophilia A or B confirmed through genetic testing and clinical evaluation.
Management
Marstacimab administered once weekly by subcutaneous injection.
Monitoring & Follow-up
No routine treatment-related laboratory monitoring required.
Risks
Warnings for thromboembolic events, hypersensitivity reactions, embryofetal toxicity, and increased laboratory values of fibrin D-dimer and prothrombin fragment 1.2.
Patient & Prescribing Data
Adults and pediatric patients aged 6 years and older with hemophilia A or B.
Marstacimab significantly reduces bleeding rates in patients with hemophilia A or B.
Clinical Best Practices
Consider patient age and inhibitor status when determining dosing.
